Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients
Movement Disorders · 2024-07 · 39 (7) · 1099-1108
DOI: 10.1002/mds.29808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 02.05.2024. Verfasst von Berta Alemany-Perna und 11 weiteren Autor:innen. Beteiligte Einrichtung: Ataxia Unit, Neurology Service, ICS/IAS, Hospital Josep Trueta/Hospital Santa Caterina, Girona/Salt, Spain. Hauptthemen laut MEDLINE: Friedreich Ataxia, Frataxin, Calcitriol, Iron-Binding Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Federacion Española de Ataxias (FEDAES), Ministerio de Ciencia e Innovación (Spain), Open Access funding provided thanks to the CRUE-CSIC agreement with Wiley and the University of Girona (UdG).
Abstract (Originalsprache)
Background
Calcitriol, the active form of vitamin D (also known as 1,25‐dihydroxycholecalciferol), improves the phenotype and increases frataxin levels in cell models of Friedreich ataxia (FRDA).
Objectives
Based on these results, we aimed measuring the effects of a calcitriol dose of 0.25 mcg/24h in the neurological function and frataxin levels when administered to FRDA patients for a year.
Methods
20 FRDA patients where recluted and 15 patients completed the treatment for a year. Evaluations of neurological function changes (SARA scale, 9‐HPT, 8‐MWT, PATA test) and quality of life (Barthel Scale and Short Form (36) Health Survey [SF‐36] quality of life questionnaire) were performed. Frataxin amounts were measured in isolated platelets obtained from these FRDA patients, from heterozygous FRDA carriers (relatives of the FA patients) and from non‐heterozygous sex and age matched controls.
Results
Although the patients did not experience any observable neurological improvement, there was a statistically significant increase in frataxin levels from initial values, 5.5 to 7.0 pg/μg after 12 months. Differences in frataxin levels referred to total protein levels were observed among sex‐ and age‐matched controls (18.1 pg/μg), relative controls (10.1 pg/μg), and FRDA patients (5.7 pg/μg). The treatment was well tolerated by most patients, and only some of them experienced minor adverse effects at the beginning of the trial.
Conclusions
Calcitriol dosage used (0.25 mcg/24 h) is safe for FRDA patients, and it increases frataxin levels. We cannot rule out that higher doses administered longer could yield neurological benefits. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ataxia Unit, Neurology Service, ICS/IAS, Hospital Josep Trueta/Hospital Santa Caterina, Girona/Salt, Spain.
- Department of Medical Sciences, University of Girona (UdG), Girona, Spain.
- Neurodegeneration and Neuroinflammacion Group, Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.
- Departament de Ciències Mèdiques Bàsiques, Institut de Recerca Biomèdica de Lleida (IRBLleida), Universitat de Lleida, Lleida, Spain.
- Neurology Service, ICS/IAS, Hospital Josep Trueta/Hospital Santa Caterina, Girona/Salt, Neurodegeneration and Neuroinflammacion Group (IDIBGI), Girona/Salt, Spain.
ORCID-Profile: Berta Alemany-Perna
Förderung
- Federacion Española de Ataxias (FEDAES)
- Ministerio de Ciencia e Innovación (Spain)
- Open Access funding provided thanks to the CRUE-CSIC agreement with Wiley and the University of Girona (UdG)
Zitieren
APA
Alemany-Perna, B., Tamarit, J., Cabiscol, E., Delaspre, F., Miguela, A., Huertas-Pons, J. M., Quiroga-Varela, A., Merchan Ruiz, M., López Domínguez, D., Ramió I Torrentà, L., Genís, D., & Ros, J. (2024). Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients. Movement Disorders, 39(7), 1099-1108. https://doi.org/10.1002/mds.29808
Vancouver
Alemany-Perna B, Tamarit J, Cabiscol E, Delaspre F, Miguela A, Huertas-Pons JM, et al. Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients. Movement Disorders. 2024;39(7):1099-1108. doi:10.1002/mds.29808
BibTeX
@article{AlemanyPerna2024,
author = {Alemany-Perna, Berta and Tamarit, Jordi and Cabiscol, Elisa and Delaspre, Fabien and Miguela, Albert and Huertas-Pons, Joana Maria and Quiroga-Varela, Ana and Merchan Ruiz, Miguel and López Domínguez, Daniel and Ramió I Torrentà, Lluís and Genís, David and Ros, Joaquim},
title = {Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients},
journal = {Movement Disorders},
year = {2024},
volume = {39},
number = {7},
pages = {1099--1108},
doi = {10.1002/mds.29808}
}
EUVIMED